Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
MWN-AI** Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) has announced that its innovative suprachoroidal delivery platform and the CLS-AX program will be prominently featured at the 25th EURETINA Congress in Paris, from September 4-7, 2025. This new technology aims to enhance treatment for various retinal diseases, such as wet age-related macular degeneration (AMD) and diabetic retinopathy, by allowing precisely targeted drug delivery into the suprachoroidal space.
Dr. Sobha Sivaprasad will present findings from the CLS-AX trial, which includes a Phase 3 design in wet AMD and a streamlined Phase 2 trial for non-proliferative diabetic retinopathy. Meanwhile, Clearside's Chief Medical Officer, Dr. Victor Chong, will engage in a panel discussion at the Ophthalmology Futures Retina Forum preceding the congress, contributing insights about the evolving strategies in retinal treatment.
The CLS-AX is a proprietary suspension of axitinib, a tyrosine kinase inhibitor, which has shown promise in previous trials for its ability to effectively blockade VEGF receptors. This targeted approach may significantly improve patient outcomes by reducing systemic exposure and potential side effects associated with traditional therapies.
Clearside’s unique SCS Microinjector allows for this innovative method of administration, potentially revolutionizing the treatment landscape for ocular conditions by providing a non-surgical, repeatable approach to drug delivery. The company aims to not only enhance efficacy but also to minimize toxicity to healthy cells. As Clearside prepares for its presentations, stakeholders are keen to observe the advancements that may bolster its position within the biopharmaceutical field focused on eye care.
MWN-AI** Analysis
Clearside Biomedical, Inc. (Nasdaq: CLSD) is certainly making waves in the biopharmaceutical sector with its innovative suprachoroidal delivery platform, as showcased at the 25th EURETINA Congress. The various presentations, particularly highlighting the CLS-AX program for addressing retinal diseases like wet age-related macular degeneration (AMD) and diabetic retinopathy, indicate a robust pipeline and strong scientific backing that may bolster investor confidence moving forward.
Given the advancements presented, including the Phase 3 trial designed for wet AMD and streamlined Phase 2 plans for diabetic retinopathy, Clearside’s position appears increasingly favorable. The SCS Microinjector, allowing for targeted drug delivery with a promising safety profile, sets Clearside apart in a competitive market. This innovative approach has the potential to provide enhanced efficacy while minimizing systemic side effects, which could disrupt existing treatment paradigms, especially in therapeutic areas characterized by limited options.
As communication around the CLS-AX and additional research evolves, investors should monitor how these presentations impact Clearside’s stock performance. A successful execution of clinical trials could lead to accelerated regulatory approvals, expanding market potential and revenue streams.
However, potential investors should remain cautious. The biopharmaceutical landscape is fraught with risks, including the unpredictability of clinical trial outcomes and market acceptance of new therapies. Additionally, Clearside's reliance on establishing partnerships and a solid financial footing should not be overlooked, especially in light of potential capital raises.
In summary, Clearside Biomedical presents a compelling buy opportunity for investors willing to embrace moderately high risk. The company’s innovative delivery system and pipeline promise a rewarding landscape, but investors should remain vigilant about clinical outcomes and market developments as the narrative unfolds.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector ® Platform for the Treatment of Multiple Retinal Diseases -
- CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad -
ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September 4 - 7, 2025 in Paris, France. Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development will also participate in a panel discussion at the preceding Ophthalmology Futures Retina Forum on September 3, 2025.
Clearside’s suprachoroidal delivery platform is designed to enable targeted treatment for multiple retinal diseases, including wet AMD, diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer.
“We are excited to showcase our SCS Microinjector ® platform and advancements with our CLS-AX program at these prominent medical meetings in Europe,” said Dr. Chong. “For CLS-AX, we have designed a Phase 3 trial in wet AMD in alignment with the U.S. FDA, and a new, streamlined Phase 2 trial design in non-proliferative diabetic retinopathy. In addition, we believe suprachoroidal delivery has the potential to provide a targeted approach for the treatment of geographic atrophy, enabling drug dispersion directly to the choroid and retina while potentially minimizing systemic and anterior segment side effects. This method may offer improved efficacy for small molecules and complement inhibition in both the retinal pigment epithelium and choroid,” Dr. Chong concluded.
25th EURETINA Congress
Title: Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update
Presenter: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK
Date: Saturday, September 6, 2025, 16:06 - 16:12 CEST
Title: A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration
Presenter: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Saturday, September 6, 2025, 14:27 - 14:33 CEST
Partner: REGENXBIO
Title: Suprachoroidal gene therapy for diabetic retinopathy (ALTITUDE study)
Presenter: Lejla Vajzovic, MD, Associate Professor of Ophthalmology at Duke University School of Medicine
Date: Thursday, September 4, 2025, 11:13 - 11:20 CEST
Ophthalmology Futures Retina Forum
Title: Geographic Atrophy & Intermediate AMD: Lessons Learned from Glaucoma & Other Chronic Disease
Panelist: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Wednesday, September 3, 2025, 18:40 - 19:10 CEST
About CLS-AX (axitinib injectable suspension)
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and demonstrated a positive safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers by compartmentalizing axitinib behind the retina, thereby limiting drug exposure to the front of the eye.
About Clearside’s Suprachoroidal Space (SCS ® ) Injection Platform and SCS Microinjector ®
Clearside’s patent protected, proprietary suprachoroidal space (SCS ® ) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company’s unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside’s patented SCS Microinjector ® can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is comprised of a syringe with a custom-designed hub and two 30-gauge hollow microneedles of varying lengths, each approximately one millimeter, optimizing insertion and suprachoroidal administration of drugs.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector ® , enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has a pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension) , is a Phase 3 ready asset for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside developed and gained approval for its first product, XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of Clearside’s product candidates, and the potential benefits of CLS-AX, Clearside’s suprachoroidal delivery technology and Clearside’s SCS Microinjector ® . These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025, Clearside’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2025 and Clearside’s other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Clearside Biomedical, Inc.
Investor and Media Contact:ir@clearsidebio.com
FAQ**
How does the performance of the CLS-AX program presented by Clearside Biomedical Inc. (CLSD) at the EURETINA Congress compare with existing treatments for wet AMD and diabetic retinopathy?
What are the key advantages of the SCS Microinjector platform developed by Clearside Biomedical Inc. (CLSD) for delivering therapies to the back of the eye, specifically in the context of targeted treatment?
Can you elaborate on the results from the Phase 2b trials of CLS-AX presented by Dr. Sobha Sivaprasad and how Clearside Biomedical Inc. (CLSD) interprets them for future regulatory submissions?
What potential risks does Clearside Biomedical Inc. (CLSD) foresee in the ongoing clinical trials for their suprachoroidal delivery technology, and how are they planning to address these challenges?
**MWN-AI FAQ is based on asking OpenAI questions about Clearside Biomedical Inc. (NASDAQ: CLSD).
NASDAQ: CLSD
CLSD Trading
-90.6% G/L:
$0.41 Last:
1,945,057 Volume:
$0.57 Open:
